Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 15;6:85. doi: 10.1038/s41698-022-00319-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — Future clinical success of WRN inhibitors hinges on three pillars: drug development, tumour profiling, and patient stratification. Development and refinement of WRN inhibitors that are potent, selective, bioavailable, and relatively safe is an absolute requirement. Improvements in genetic and epigenetic tumour profiling through deep sequencing, liquid biopsies, and other technologies would provide a clearer picture of intra-tumour heterogeneity. Moreover, MSI testing will need to be coupled with (TA)_n repeat expansion profiling to predict the potential of WRN inhibition. Finally, risk analysis through cancer modelling and biomarker identification will invariably improve patient stratification. Figure was created with BioRender.com.